Drug intelligence / Profile preview

PTX-102

Development stage: Unknown
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PTX-102 is an mRNA-lipid nanoparticle (LNP) cancer vaccine being developed by Providence Therapeutics for the treatment of advanced solid tumors. The vaccine encodes tumor-specific precision antigens designed to elicit an adaptive anti-tumor immune response against cancer cells. It is currently in Phase 1 clinical development as a first-in-human, open-label, multicenter clinical trial evaluating its safety and immunogenicity in patients with various solid tumors. This program represents an application of Providence's mRNA platform technology to oncology and is distinct from their personalized cancer vaccine program, PTX-101.

Other names: PTX-102 mRNA vaccinePTX102 mRNA vaccinePTX 102 mRNA vaccine

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on PTX-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-102.

Explore the full profile